𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene transfer and therapy clinical trials – update. Part 2: gene delivery systems used and genes transferred

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
162 KB
Volume
1
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis

Part 2*: Gene Delivery Systems Used and Genes Transferred Delivery systems Gene delivery systems are based either on physicochemical methods or on biological methods (or a combination of the two). Gene Delivery systems used in humans to date are: Physico-chemical methods Biological methods Gene gun, or biolistics Recombinant adenovirus In situ naked DNA injection Adeno-Associated Virus RNA transfer Poxvirus Cationic lipids and Polycations Retrovirus Other transfection methods Herpesvirus (including cacium phosphate) Electroporation * Part 1 ± Countries, diseases, routes of administration and clinical trial phases was published in J Gene Med 1999; 1 : 71±73.

📜 SIMILAR VOLUMES

Gene transfer and therapy clinical trial
Gene transfer and therapy clinical trials – update. Part I: Countries, Diseases, Clinical trial phases, Routes of administration
✍ Thomas Valère 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

Part I\*: Countries, Diseases, Clinical trial phases, Routes of administration ## Countries Countries where clinical trials are being performed or have been approved Gene therapy trials have now been initiated on all ®ve continents but the large majority of trials are being performed in the USA

Acquired immunity in nude mice induced b
Acquired immunity in nude mice induced by expression of the IL-2 or IL-4 gene in human pancreatic carcinoma cells and anti-tumor effect generated by In vivo gene transfer using retrovirus
✍ Masaki Kimura; Yu Yoshida; Mitsuro Narita; Keizo Takenaga; Toshinao Takenouchi; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 330 KB 👁 2 views

We have examined the anti-tumor effect in nude mice caused by human pancreatic cancer cells (AsPC-1) modified to secrete IL-2 or IL-4. Loss of tumorigenicity of cytokineproducing, but not wild-type, cells was observed despite their unaltered in vitro proliferation rates; and these anti-tumor effects